Vistagen, Inc.


Aug 23, 05

NEW STORY
17:00 ET Lantos Affirms Support of Expanded Stem Cell Research - Applauds Commitment by VistaGen Employees and Investors

 
Aug 11, 05

07:15 ET VistaGen Therapeutics Secures Development Support for New Drug Candidate for Huntington's Disease

 
Jul 12, 05

07:15 ET VistaGen Therapeutics Awarded $197,000 NIH Grant for Expanded Preclinical Development of New Drug Candidate for Neuropathic Pain

 
May 24, 05

07:15 ET VistaGen Therapeutics Awarded $3,700,000 NIH Drug Development Grant for Lead Epilepsy Drug Candidate

 
Nov 04, 04

07:08 ET VistaGen Secures More Key Embryonic Stem Cell Technology for Leading Edge Diabetes Research

 
Oct 14, 04

07:15 ET VistaGen Creates Clinical Advisory Board

 
Oct 13, 04

07:15 ET VistaGen Therapeutics and Sanwa Announce First Embryonic Stem Cell Research Partnership Focused on New Treatments for Diabetes

 
Aug 31, 04

07:15 ET VistaGen Expands Board and Senior Management

 
Jan 12, 04

07:15 ET VistaGen Awarded NIH Research Grant for Advanced Preclinical Development of Lead Epilepsy Drug Candidate

 
Nov 19, 03

07:15 ET VistaGen Therapeutics Acquires Artemis Neuroscience, Inc. - Enters Late-Stage Preclinical Development Program for Lead Epilepsy Drug Candidate -

 
Apr 08, 03

07:15 ET VistaGen Therapeutics and Sanwa Announce Stem Cell Biology Partnership And Financing

 
Sep 04, 02

07:45 ET VistaGen Awarded $1.7 Million NIH Phase 2 SBIR Grant for Novel Stem Cell-Based Predictive Assays

 
Jul 09, 02

07:45 ET VistaGen Receives NIH Funding for Development of Biomathematical Models Of Molecular Toxicity

 
Apr 15, 02

07:15 ET VistaGen Therapeutics and Novartis Sign Murine Stem Cell Partnership To Explore New in Vitro Toxicity Models for Drug Candidates

 


Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.
Terms and conditions, including restrictions on redistribution, apply.
Copyright © 1996-2005 PR Newswire Association LLC. ALL Rights Reserved.
A United Business Media company.